In hepatocellular and lung cancer, increased expression of ARHGEF39 has been reported as a prognostic factor for tumour size and patient survival (Zhou et al., 2018; Gao and Jia, 2019; Xu et al., 2019; Cooke et al., 2021). The gene discussed is ARHGEF39; the disease is lung cancer.